Dashboard
Manage Tickers

CRSP


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-buy-on-crispr-therapeutics-maintains-81-price-target
Needham Reiterates Buy on CRISPR Therapeut...
10/10/2025 15:04:22

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $81 price target.

crispr-therapeutics-reports-new-preclinical-data-from-syntase-gene-editing-platform-for-treatment-of-alpha-1-antitrypsin-deficiency
CRISPR Therapeutics Reports New Preclinica...
10/10/2025 12:13:27

-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profil...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/08/2025 17:35:32

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/03/2025 17:35:44

crispr-therapeutics-to-present-preclinical-data-on-alpha-1-antitrypsin-deficiency-utilizing-novel-syntase-gene-editing-technology
CRISPR Therapeutics To Present Preclinical...
10/01/2025 12:04:16

hc-wainwright--co-reiterates-buy-on-crispr-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on CRIS...
09/23/2025 10:59:59

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80...

crispr-therapeutics-and-sirius-therapeutics-announce-first-patient-dosed-in-phase-2-clinical-trial-of-srsd107-factor-xi-sirna-for-prevention-of-vte-in-patients-undergoing-tka
CRISPR Therapeutics And Sirius Therapeutic...
09/22/2025 12:34:00

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...

my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years
My Top Biotech Stock Picks And Portfolio S...
09/18/2025 17:10:48

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

jp-morgan-initiates-coverage-on-crispr-therapeutics-with-overweight-rating-announces-price-target-of-70
JP Morgan Initiates Coverage On CRISPR The...
09/18/2025 10:55:54

JP Morgan analyst Brian Cheng initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight rating and announces...

how-is-the-market-feeling-about-crispr-therapeutics
How Is The Market Feeling About CRISPR The...
09/12/2025 18:00:46

Core News & Articles
10 Health Care Stocks Whale Activity In To...
09/02/2025 17:35:29

peering-into-crispr-therapeuticss-recent-short-interest
Peering Into CRISPR Therapeutics's Recent ...
08/22/2025 13:00:48

cathie-woods-arkk-is-beating-big-tech-like-its-2020-again--but-with-a-twist
Cathie Wood's ARKK Is Beating Big Tech Lik...
08/19/2025 15:40:03

Cathie Wood's ARK Innovation ETF is outperforming tech market again in 2025, driven by AI breakthroughs and the return of i...

cathie-woods-top-10-stock-picks-unpacking-ark-funds-innovation-picks-for-the-next-decade
Cathie Wood's Top 10 Stock Picks: Unpackin...
08/14/2025 17:02:25

Ark Invest has six main ETFs with several around for more than 10 years. A look at the top 10 holdings across the six funds and...

hc-wainwright--co-maintains-buy-on-crispr-therapeutics-raises-price-target-to-80
HC Wainwright & Co. Maintains Buy on CRISP...
08/07/2025 11:54:08

HC Wainwright & Co. analyst Mitchell Kapoor maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price ...

barclays-maintains-equal-weight-on-crispr-therapeutics-raises-price-target-to-56
Barclays Maintains Equal-Weight on CRISPR ...
08/06/2025 14:11:44

Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and raises the price target from ...

cathie-woods-ark-dumps-block-stock-worth-48-million-as-bitcoin-heavy-company-preps-q2-results
Cathie Wood's Ark Dumps Block Stock Worth ...
08/06/2025 01:48:06

Cathie Wood-led Ark Invest executed a significant trade in Block Inc. (NYSE:XYZ) on Tuesday.

chardan-capital-maintains-buy-on-crispr-therapeutics-maintains-82-price-target
Chardan Capital Maintains Buy on CRISPR Th...
08/05/2025 22:19:41

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $82 price target.

rbc-capital-maintains-sector-perform-on-crispr-therapeutics-raises-price-target-to-42
RBC Capital Maintains Sector Perform on CR...
08/05/2025 13:15:50

RBC Capital analyst Luca Issi maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Sector Perform and raises the price target ...

correction-crispr-therapeutics-q2-adj-eps-129-beats-147-estimate-sales-892000k-miss-6255m-estimate
CORRECTION: CRISPR Therapeutics Q2 Adj. EP...
08/04/2025 21:05:23

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.29) per share which beat the analyst consensus estimate of $...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION